| 1/26/2021 |
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team |
|
... of experience investing in public and private biopharmaceutical and medical device companies. Dr. Cha was previously a Managing Partner at Vivo Capital. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND ... by Merz), Biodel (NASDAQ: BIOD), and NextWave Pharmaceuticals (acquired by Pfizer). Dr. Cha is a co-founder of the annual Dermatology Summit and Dermatology Innovation Forum. He also worked at Oracle Corporation in pharmaceutical consulting ... |
| 8/7/2020 |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020 |
PR Newswire |
... Pfizer Inc. (NYSE: PFE ), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare,Vivo Capital, and others. On July 15 th , the Company announced that the first patient had been dosed in a Phase 1 clinical trial designed to evaluate the safety and tolerability of EPI-7386 in mCRPC patients who failed standard of care treatments, including second generation anti-androgens. The trial, to be conducted at five sites in ... |
| 8/7/2020 |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020 |
PR Newswire |
... Pfizer Inc. (NYSE: PFE ), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare,Vivo Capital, and others. On July 15 th , the Company announced that the first patient had been dosed in a Phase 1 clinical trial designed to evaluate the safety and tolerability of EPI-7386 in mCRPC patients who failed standard of care treatments, including second generation anti-androgens. The trial, to be conducted at five sites in ... |
| 7/31/2020 |
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000 |
PR Newswire |
... Pfizer Inc. (NYSE: PFE ), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital. ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. Such proceeds will primarily be used to expand the ongoing Phase 1 dose-escalation and extension studies and allow the potential for ... |
| 7/31/2020 |
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000 |
PR Newswire |
... Pfizer Inc. (NYSE: PFE ), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital. ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. Such proceeds will primarily be used to expand the ongoing Phase 1 dose-escalation and extension studies and allow the potential for ... |
| 7/31/2020 |
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000 |
PR Newswire |
... Pfizer Inc. (NYSE: PFE ), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital. ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. Such proceeds will primarily be used to expand the ongoing Phase 1 dose-escalation and extension studies and allow the potential for ... |
| 7/2/2020 |
Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | FierceBiotech |
FierceBiotech |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. As part of the financing, Jason Pitts, Ph.D., principal at Sofinnova Investments, joins the company's board. He said: “We believe Bolt is well-positioned to execute on its vision of developing immuno-oncology therapies with the potential to generate systemic immunological memory and provide durable clinical benefit. I look forward to helping the company ... |
| 7/2/2020 |
Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | FierceBiotech |
FierceBiotech |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. As part of the financing, Jason Pitts, Ph.D., principal at Sofinnova Investments, joins the company's board. He said: “We believe Bolt is well-positioned to execute on its vision of developing immuno-oncology therapies with the potential to generate systemic immunological memory and provide durable clinical benefit. I look forward to helping the company ... |
| 7/2/2020 |
Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | FierceBiotech |
FierceBiotech |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. As part of the financing, Jason Pitts, Ph.D., principal at Sofinnova Investments, joins the company's board. He said: “We believe Bolt is well-positioned to execute on its vision of developing immuno-oncology therapies with the potential to generate systemic immunological memory and provide durable clinical benefit. I look forward to helping the company ... |
| 7/2/2020 |
Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | FierceBiotech |
FierceBiotech |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. As part of the financing, Jason Pitts, Ph.D., principal at Sofinnova Investments, joins the company's board. He said: “We believe Bolt is well-positioned to execute on its vision of developing immuno-oncology therapies with the potential to generate systemic immunological memory and provide durable clinical benefit. I look forward to helping the company ... |
| 7/2/2020 |
Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic | FierceBiotech |
FierceBiotech |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. As part of the financing, Jason Pitts, Ph.D., principal at Sofinnova Investments, joins the company's board. He said: “We believe Bolt is well-positioned to execute on its vision of developing immuno-oncology therapies with the potential to generate systemic immunological memory and provide durable clinical benefit. I look forward to helping the company ... |
| 7/1/2020 |
Bolt Biotherapeutics Closes $93.5 Million Series C Financing |
PR Newswire |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. Bolt is pioneering a new category of immunotherapies that combine the precision of antibody targeting with the power of the innate immune system via activating myeloid cells and reprogramming the tumor microenvironment. Bolt has raised more than $170 million since its founding in 2015, and this new round of funding will support the continued ... |
| 7/1/2020 |
Bolt Biotherapeutics Closes $93.5 Million Series C Financing |
PR Newswire |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. Bolt is pioneering a new category of immunotherapies that combine the precision of antibody targeting with the power of the innate immune system via activating myeloid cells and reprogramming the tumor microenvironment. Bolt has raised more than $170 million since its founding in 2015, and this new round of funding will support the continued ... |
| 7/1/2020 |
Bolt Biotherapeutics Closes $93.5 Million Series C Financing |
PR Newswire |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. Bolt is pioneering a new category of immunotherapies that combine the precision of antibody targeting with the power of the innate immune system via activating myeloid cells and reprogramming the tumor microenvironment. Bolt has raised more than $170 million since its founding in 2015, and this new round of funding will support the continued ... |
| 7/1/2020 |
Bolt Biotherapeutics Closes $93.5 Million Series C Financing |
PR Newswire |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. Bolt is pioneering a new category of immunotherapies that combine the precision of antibody targeting with the power of the innate immune system via activating myeloid cells and reprogramming the tumor microenvironment. Bolt has raised more than $170 million since its founding in 2015, and this new round of funding will support the continued ... |
| 7/1/2020 |
Bolt Biotherapeutics Closes $93.5 Million Series C Financing |
PR Newswire |
... Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. Bolt is pioneering a new category of immunotherapies that combine the precision of antibody targeting with the power of the innate immune system via activating myeloid cells and reprogramming the tumor microenvironment. Bolt has raised more than $170 million since its founding in 2015, and this new round of funding will support the continued ... |
| 5/12/2020 |
Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. |
Business Insider |
... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... into other therapy areas. Concerto announced the deal, partnerships with Pfizer and Janssen, and a new research platform at the J.P. Morgan Morgan Healthcare Conference in January. Called eurekaHealth 3.0, the platform combines data from ... |
| 5/12/2020 |
Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. |
Business Insider |
... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... into other therapy areas. Concerto announced the deal, partnerships with Pfizer and Janssen, and a new research platform at the J.P. Morgan Morgan Healthcare Conference in January. Called eurekaHealth 3.0, the platform combines data from ... |
| 5/12/2020 |
Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. |
Business Insider |
... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... into other therapy areas. Concerto announced the deal, partnerships with Pfizer and Janssen, and a new research platform at the J.P. Morgan Morgan Healthcare Conference in January. Called eurekaHealth 3.0, the platform combines data from ... |
| 5/12/2020 |
Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. |
Business Insider |
... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... into other therapy areas. Concerto announced the deal, partnerships with Pfizer and Janssen, and a new research platform at the J.P. Morgan Morgan Healthcare Conference in January. Called eurekaHealth 3.0, the platform combines data from ... |
| 5/12/2020 |
Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. |
Business Insider |
... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... into other therapy areas. Concerto announced the deal, partnerships with Pfizer and Janssen, and a new research platform at the J.P. Morgan Morgan Healthcare Conference in January. Called eurekaHealth 3.0, the platform combines data from ... |
| 5/12/2020 |
Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. |
Business Insider |
... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... into other therapy areas. Concerto announced the deal, partnerships with Pfizer and Janssen, and a new research platform at the J.P. Morgan Morgan Healthcare Conference in January. Called eurekaHealth 3.0, the platform combines data from ... |
| 5/12/2020 |
Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. |
Business Insider |
... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... into other therapy areas. Concerto announced the deal, partnerships with Pfizer and Janssen, and a new research platform at the J.P. Morgan Morgan Healthcare Conference in January. Called eurekaHealth 3.0, the platform combines data from ... |
| 10/8/2019 |
Bolt Biotherapeutics Announces Scientific Advisory Board with the Appointment of Drs. Larry Fong, Roy Herbst and Bruce Roth |
PR Newswire |
... small molecule drug discovery and co-leader of gRED research. Before that, he served as vice president of chemistry at Pfizer Global Research and Development, Ann Arbor Laboratories, and prior to that, was an adjunct ... by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com where you will find complete biographies of Bolt's SAB ... |